S. 3105: Increase Support for Life-saving Endocrine Transplantation Act

This bill, known as the Increase Support for Life-saving Endocrine Transplantation Act (or ISLET Act), aims to enhance the regulation of human cadaveric islets for transplantation. Here’s a breakdown of its main components:

Purpose of the Bill

The bill specifically targets the regulation of human cadaveric islets, which are clusters of cells in the pancreas that produce insulin. These islets are important for people with diabetes, particularly those who may benefit from transplantation as a treatment option.

Amendment to the Public Health Service Act

The bill proposes to amend existing legislation to include human cadaveric islets alongside other organs, such as the pancreas, within the regulations that govern organ transplants.

Declassification of Human Cadaveric Islets

It clarifies that human cadaveric islets are not to be considered as:

• Drugs - as defined by the Federal Food, Drug, and Cosmetic Act.
• Biological products - as defined by Public Health Service Act.
• Human cells, tissues, or cellular or tissue-based products (HCT/Ps) - as defined in relevant regulations.

Updates to Regulations

The bill mandates that the Secretary of Health and Human Services must update existing regulations within one year of the bill's enactment. This update will focus on incorporating the new provisions regarding human cadaveric islets into the regulatory framework of organ transplantation.

Reporting Requirements

Additionally, the Secretary is required to report to Congress on the progress made in updating these regulations within six months of the Act's enactment. This ensures that Congress is kept informed about the implementation process regarding the regulation of human cadaveric islet transplants.

Overall Intent

The overall intent of the legislation is to enhance the regulatory framework surrounding the transplantation of human cadaveric islets, potentially expanding treatment options for patients with diabetes while ensuring safety and efficacy in the process.

Relevant Companies

None found